Barinthus Biotherapeutics

This article has multiple issues. Please help improve it or discuss these issues on the talk page. (Learn how and when to remove these messages) The topic of this article may not meet Wikipedia's notability guidelines for companies and organizations. Please help to demonstrate the notability of the topic by citing reliable secondary sources that are independent of the topic and provide significant coverage of it beyond a mere trivial mention. If notability cannot be shown, the article is likely to be merged, redirected, or deleted. Find sources: "Barinthus Biotherapeutics" – news · newspapers · books · scholar · JSTOR (November 2023) (Learn how and when to remove this message) This article relies excessively on references to primary sources. Please improve this article by adding secondary or tertiary sources. Find sources: "Barinthus Biotherapeutics" – news · newspapers · books · scholar · JSTOR (November 2023) (Learn how and when to remove this message) (Learn how and when to remove this message)

Barinthus Biotherapeutics plc

Company type	Public
Traded as	Nasdaq: BRNS
Industry	Vaccines Immunotherapy Biotechnology
Founded	2016; 8 years ago (2016)
Founders	Sarah Gilbert Adrian V. S. Hill
Headquarters	Oxford Science Park, Oxford , United Kingdom
Website	barinthusbio.com

Barinthus Biotherapeutics plc (formerly Vaccitech plc) is a biotechnology company developing immunotherapies for infectious diseases, cancer and autoimmune diseases such as hepatitis B, HPV and prostate cancer.^[1][2] Formerly known as Vaccitech plc, in November 2023 the company announced that it had renamed itself to Barinthus Biotherapeutics plc. As of 2024, the company employs more than 100 people.